• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

埃博拉病毒感染的免疫学视角及为抗击该疾病采取的各种治疗措施。

Immunological Perspective for Ebola Virus Infection and Various Treatment Measures Taken to Fight the Disease.

作者信息

Jain Sahil, Khaiboullina Svetlana F, Baranwal Manoj

机构信息

Department of Biotechnology, Thapar Institute of Engineering & Technology, Patiala, Punjab 147004, India.

Department of Microbiology and Immunology, University of Nevada, Reno, NV 89557, USA.

出版信息

Pathogens. 2020 Oct 17;9(10):850. doi: 10.3390/pathogens9100850.

DOI:10.3390/pathogens9100850
PMID:33080902
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7603231/
Abstract

Ebolaviruses, discovered in 1976, belongs to the family, which also includes Marburg and Lloviu viruses. They are negative-stranded RNA viruses with six known species identified to date. Ebola virus (EBOV) is a member of species and can cause the Ebola virus disease (EVD), an emerging zoonotic disease that results in homeostatic imbalance and multi-organ failure. There are three EBOV outbreaks documented in the last six years resulting in significant morbidity (> 32,000 cases) and mortality (> 13,500 deaths). The potential factors contributing to the high infectivity of this virus include multiple entry mechanisms, susceptibility of the host cells, employment of multiple immune evasion mechanisms and rapid person-to-person transmission. EBOV infection leads to cytokine storm, disseminated intravascular coagulation, host T cell apoptosis as well as cell mediated and humoral immune response. In this review, a concise recap of cell types targeted by EBOV and EVD symptoms followed by detailed run-through of host innate and adaptive immune responses, virus-driven regulation and their combined effects contributing to the disease pathogenesis has been presented. At last, the vaccine and drug development initiatives as well as challenges related to the management of infection have been discussed.

摘要

埃博拉病毒于1976年被发现,属于该病毒家族,该家族还包括马尔堡病毒和洛维乌病毒。它们是负链RNA病毒,迄今已鉴定出六个已知物种。埃博拉病毒(EBOV)是该物种的成员,可引起埃博拉病毒病(EVD),这是一种新出现的人畜共患病,可导致体内稳态失衡和多器官衰竭。在过去六年中记录了三次埃博拉病毒疫情,导致大量发病(>32000例)和死亡(>13500人死亡)。导致这种病毒高传染性的潜在因素包括多种进入机制、宿主细胞的易感性、多种免疫逃避机制的运用以及快速的人际传播。埃博拉病毒感染会导致细胞因子风暴、弥散性血管内凝血、宿主T细胞凋亡以及细胞介导和体液免疫反应。在这篇综述中,简要回顾了埃博拉病毒靶向的细胞类型和埃博拉病毒病症状,随后详细阐述了宿主固有免疫和适应性免疫反应、病毒驱动的调节及其对疾病发病机制的综合影响。最后,讨论了疫苗和药物开发计划以及与感染管理相关的挑战。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e45/7603231/179b943076bf/pathogens-09-00850-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e45/7603231/b6b4a3ba071d/pathogens-09-00850-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e45/7603231/179b943076bf/pathogens-09-00850-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e45/7603231/b6b4a3ba071d/pathogens-09-00850-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e45/7603231/179b943076bf/pathogens-09-00850-g002.jpg

相似文献

1
Immunological Perspective for Ebola Virus Infection and Various Treatment Measures Taken to Fight the Disease.埃博拉病毒感染的免疫学视角及为抗击该疾病采取的各种治疗措施。
Pathogens. 2020 Oct 17;9(10):850. doi: 10.3390/pathogens9100850.
2
Transcriptional Analysis of Lymphoid Tissues from Infected Nonhuman Primates Reveals the Basis for Attenuation and Immunogenicity of an Ebola Virus Encoding a Mutant VP35 Protein.从感染的非人类灵长类动物的淋巴组织转录分析揭示了编码突变 VP35 蛋白的埃博拉病毒减毒和免疫原性的基础。
J Virol. 2021 Feb 24;95(6). doi: 10.1128/JVI.01995-20.
3
Dendritic Cells Generated From , a Likely Filovirus Reservoir Host, Are Susceptible to and Activated by Zaire Ebolavirus Infection.来源于可能的丝状病毒储存宿主的树突状细胞容易被扎伊尔埃博拉病毒感染和激活。
Front Immunol. 2019 Oct 11;10:2414. doi: 10.3389/fimmu.2019.02414. eCollection 2019.
4
Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection.VSV-EBOV 疫苗接种诱导的抗病毒先天免疫反应有助于快速保护。
mBio. 2019 May 28;10(3):e00597-19. doi: 10.1128/mBio.00597-19.
5
Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.基于痘病毒的埃博拉病毒表达 GP 和 VP40 蛋白疫苗候选物的免疫原性和疗效的差异。
J Virol. 2018 May 14;92(11). doi: 10.1128/JVI.00363-18. Print 2018 Jun 1.
6
To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity.是B还是非B:重组水疱性口炎病毒载体埃博拉病毒糖蛋白疫苗(rVSV-EBOV-GP)的保护机制以及固有免疫和适应性免疫的作用
Microorganisms. 2020 Sep 25;8(10):1473. doi: 10.3390/microorganisms8101473.
7
Survival Is Associated with Early Activation of Adaptive Immunity and Reduced Myeloid-Derived Suppressor Cell Signaling.存活与适应性免疫的早期激活和髓系来源的抑制性细胞信号的减少相关。
mBio. 2021 Aug 31;12(4):e0151721. doi: 10.1128/mBio.01517-21. Epub 2021 Aug 10.
8
A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques.双价、球形病毒样颗粒疫苗增强恒河猴对致病性埃博拉病毒免疫反应的广度。
J Virol. 2020 Apr 16;94(9). doi: 10.1128/JVI.01884-19.
9
Ebola Virus Binding to Tim-1 on T Lymphocytes Induces a Cytokine Storm.埃博拉病毒与 T 淋巴细胞上的 Tim-1 结合会引发细胞因子风暴。
mBio. 2017 Sep 26;8(5):e00845-17. doi: 10.1128/mBio.00845-17.
10
Ebola Virus Glycoprotein Induces an Innate Immune Response via TLR4.埃博拉病毒糖蛋白通过Toll样受体4诱导先天性免疫反应。
Front Microbiol. 2017 Aug 17;8:1571. doi: 10.3389/fmicb.2017.01571. eCollection 2017.

引用本文的文献

1
Identification of Natural Compounds as Potential COVID-19 Main Protease (Mpro) Inhibitors: A Comprehensive Study and Evidence.鉴定天然化合物作为潜在的新型冠状病毒主要蛋白酶(Mpro)抑制剂:一项全面研究及证据
Curr Pharm Des. 2025;31(30):2416-2437. doi: 10.2174/0113816128344055250220100720.
2
How to prepare for the next inevitable Ebola outbreak: lessons from West Africa.如何为下一次不可避免的埃博拉疫情做准备:来自西非的教训。
Nat Med. 2024 Dec;30(12):3413-3416. doi: 10.1038/s41591-024-03295-x.
3
Treatment of Acute and Long-COVID, Diabetes, Myocardial Infarction, and Alzheimer's Disease: The Potential Role of a Novel Nano-Compound-The Transdermal Glutathione-Cyclodextrin Complex.

本文引用的文献

1
The journey of remdesivir: from Ebola to COVID-19.瑞德西韦的历程:从埃博拉到新冠病毒。
Drugs Context. 2020 May 22;9. doi: 10.7573/dic.2020-4-14. eCollection 2020.
2
Ebola.埃博拉
N Engl J Med. 2020 May 7;382(19):1832-1842. doi: 10.1056/NEJMra1901594.
3
A Vaccine against Ebola Virus.埃博拉病毒疫苗。
急性和长期新冠、糖尿病、心肌梗死及阿尔茨海默病的治疗:一种新型纳米化合物——经皮谷胱甘肽 - 环糊精复合物的潜在作用
Antioxidants (Basel). 2024 Sep 12;13(9):1106. doi: 10.3390/antiox13091106.
4
Pathogenic differences of cynomolgus macaques after Taï Forest virus infection depend on the viral stock propagation.感染塞内加尔猕猴后,依病毒株繁殖方式而定的 Taï 森林病毒的致病性差异。
PLoS Pathog. 2024 Jun 11;20(6):e1012290. doi: 10.1371/journal.ppat.1012290. eCollection 2024 Jun.
5
Novel Antiviral Molecules against Ebola Virus Infection.抗埃博拉病毒感染的新型抗病毒分子
Int J Mol Sci. 2023 Sep 30;24(19):14791. doi: 10.3390/ijms241914791.
6
Single-dose VSV-based vaccine protects cynomolgus macaques from disease after Taï Forest virus infection.单次剂量基于水疱性口炎病毒的疫苗可预防感染塔伊森林病毒的食蟹猴发病。
Emerg Microbes Infect. 2023 Dec;12(2):2239950. doi: 10.1080/22221751.2023.2239950.
7
Single-cell profiling of lncRNA expression during Ebola virus infection in rhesus macaques.在恒河猴感染埃博拉病毒过程中对长链非编码 RNA 表达的单细胞分析。
Nat Commun. 2023 Jun 30;14(1):3866. doi: 10.1038/s41467-023-39627-7.
8
Immune correlates of protection for SARS-CoV-2, Ebola and Nipah virus infection.SARS-CoV-2、埃博拉病毒和尼帕病毒感染的免疫保护相关性。
Front Immunol. 2023 Apr 17;14:1156758. doi: 10.3389/fimmu.2023.1156758. eCollection 2023.
9
Epidemiology of Ebolaviruses from an Etiological Perspective.从病因学角度看埃博拉病毒的流行病学
Pathogens. 2023 Feb 3;12(2):248. doi: 10.3390/pathogens12020248.
10
RNA Viruses, Pregnancy and Vaccination: Emerging Lessons from COVID-19 and Ebola Virus Disease.RNA病毒、妊娠与疫苗接种:来自新冠病毒病和埃博拉病毒病的新经验教训
Pathogens. 2022 Jul 15;11(7):800. doi: 10.3390/pathogens11070800.
Cell. 2020 Apr 2;181(1):6. doi: 10.1016/j.cell.2020.03.011.
4
Ebola virus disease.埃博拉病毒病。
Nat Rev Dis Primers. 2020 Feb 20;6(1):13. doi: 10.1038/s41572-020-0147-3.
5
Ebola virus disease: An emerging and re-emerging viral threat.埃博拉病毒病:一种新出现和再现的病毒威胁。
J Autoimmun. 2020 Jan;106:102375. doi: 10.1016/j.jaut.2019.102375. Epub 2019 Dec 3.
6
Griffithsin, a Highly Potent Broad-Spectrum Antiviral Lectin from Red Algae: From Discovery to Clinical Application.红藻源高活性广谱抗病毒凝集素 Griffithsin:从发现到临床应用。
Mar Drugs. 2019 Oct 6;17(10):567. doi: 10.3390/md17100567.
7
Pulmonary Involvement during the Ebola Virus Disease.埃博拉病毒病期间的肺部受累。
Viruses. 2019 Aug 24;11(9):780. doi: 10.3390/v11090780.
8
Current status of small molecule drug development for Ebola virus and other filoviruses.埃博拉病毒和其他丝状病毒小分子药物研发的现状。
Curr Opin Virol. 2019 Apr;35:42-56. doi: 10.1016/j.coviro.2019.03.001. Epub 2019 Apr 16.
9
Bombali Virus in Mops condylurus Bat, Kenya.肯尼亚大狐蝠中携带的邦巴利病毒。
Emerg Infect Dis. 2019 May;25(5):955-957. doi: 10.3201/eid2505.181666.
10
Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania.两剂次 Ad26.ZEBOV 和 MVA-BN-Filo 埃博拉疫苗异源接种方案的安全性和免疫原性:乌干达和坦桑尼亚的 1 期随机临床试验 12 个月数据
J Infect Dis. 2019 Jun 5;220(1):46-56. doi: 10.1093/infdis/jiz070.